Literature DB >> 11106679

Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy.

P Correa1, E T Fontham, J C Bravo, L E Bravo, B Ruiz, G Zarama, J L Realpe, G T Malcom, D Li, W D Johnson, R Mera.   

Abstract

BACKGROUND: Previous research has identified a high risk of gastric carcinoma as well as a high prevalence of cancer precursor lesions in rural populations living in the province of Nariño, Colombia, in the Andes Mountains.
METHODS: A randomized, controlled chemoprevention trial was conducted in subjects with confirmed histologic diagnoses of multifocal nonmetaplastic atrophy and/or intestinal metaplasia, two precancerous lesions. Individuals were assigned to receive anti-Helicobacter pylori triple therapy and/or dietary supplementation with ascorbic acid, beta-carotene, or their corresponding placebos. Gastric biopsy specimens taken at baseline were compared with those taken at 72 months. Relative risks of progression, no change, and regression from multifocal nonmetaplastic atrophy and intestinal metaplasia were analyzed with multivariate polytomous logistic regression models to estimate treatment effects. All statistical tests were two-sided.
RESULTS: All three basic interventions resulted in statistically significant increases in the rates of regression: Relative risks were 4.8 (95% confidence interval [CI] = 1.6-14.2) for anti-H. pylori treatment, 5. 1 (95% CI = 1.7-15.0) for beta-carotene treatment, and 5.0 (95% CI = 1.7-14.4) for ascorbic acid treatment in subjects with atrophy. Corresponding relative risks of regression in subjects with intestinal metaplasia were 3.1 (95% CI = 1.0-9.3), 3.4 (95% CI = 1.1-9.8), and 3.3 (95% CI = 1.1-9.5). Combinations of treatments did not statistically significantly increase the regression rates. Curing the H. pylori infection (which occurred in 74% of the treated subjects) produced a marked and statistically significant increase in the rate of regression of the precursor lesions (relative risks = 8.7 [95% CI = 2.7-28.2] for subjects with atrophy and 5.4 [95% CI = 1.7-17.6] for subjects with intestinal metaplasia).
CONCLUSIONS: In the very high-risk population studied, effective anti-H. pylori treatment and dietary supplementation with antioxidant micronutrients may interfere with the precancerous process, mostly by increasing the rate of regression of cancer precursor lesions, and may be an effective strategy to prevent gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106679     DOI: 10.1093/jnci/92.23.1881

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  174 in total

1.  Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia.

Authors:  M F Dixon
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  Recent developments in gastroenterology.

Authors:  Paul Moayyedi; Alex Ford
Journal:  BMJ       Date:  2002-12-14

3.  P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions.

Authors:  James Sul; Guo-Pei Yu; Qing-Yi Lu; Ming-Lan Lu; Veronica Wendy Setiawan; Ming-Rong Wang; Chun Hua Guo; Shun-Zhang Yu; Lina Mu; Lin Cai; Robert C Kurtz; Zuo-Feng Zhang
Journal:  Cancer Lett       Date:  2005-08-19       Impact factor: 8.679

4.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Prediagnostic plasma vitamin C and risk of gastric adenocarcinoma and esophageal squamous cell carcinoma in a Chinese population.

Authors:  Tram Kim Lam; Neal D Freedman; Jin-Hu Fan; You-Lin Qiao; Sanford M Dawsey; Philip R Taylor; Christian C Abnet
Journal:  Am J Clin Nutr       Date:  2013-09-11       Impact factor: 7.045

6.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

Review 7.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

8.  Gastric cancer-a clinicopathological study in a tertiary care centre of North-eastern India.

Authors:  Arun Kumar Barad; Sanjeet Kumar Mandal; Hiriyur S Harsha; Birkumar M Sharma; Th Sudhirchandra Singh
Journal:  J Gastrointest Oncol       Date:  2014-04

9.  Vitamin C supplementation does not protect L-gulono-gamma-lactone oxidase-deficient mice from Helicobacter pylori-induced gastritis and gastric premalignancy.

Authors:  Chung-Wei Lee; Xiang-Dong Wang; Kuo-Liong Chien; Zhongming Ge; Barry H Rickman; Arlin B Rogers; Andrea Varro; Mark T Whary; Timothy C Wang; James G Fox
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

10.  Effect modification by vitamin C on the relation between gastric cancer and Helicobacter pylori.

Authors:  Dae-Sung Kim; Moo-Song Lee; Young-Sik Kim; Dong-Hyun Kim; Jong-Myon Bae; Myung-Hee Shin; Yoon-Ok Ahn
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.